Chan, Edward M.

Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non–Small Cell Lung Cancer, and Other Solid Tumors

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., et al. (2016) · Cancer Discovery

Advanced Breast Cancer TherapiesPI3K/AKT/mTOR signaling in cancer

Cited by 743

Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine

Gelbert, L. M., Cai, S., Lin, X., Sanchez-Martinez, C., del Prado, M., Lallena, M. J., Torres, R., Ajamie, R. T., Wishart, G. N., Flack, R. S., et al. (2014) · Investigational New Drugs

Cancer-related Molecular PathwaysAdvanced Breast Cancer Therapies

Cited by 577

The CDK4/6 inhibitor LY2835219 overcomes vemurafenib resistance resulting from MAPK reactivation and cyclin D1 upregulation

Yadav, V., Burke, T. F., Huber, L., Van Horn, R. D., Zhang, Y., Buchanan, S. G., Chan, E. M., Starling, J. J., Beckmann, R. P., & Peng, S.-B. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysAdvanced Breast Cancer Therapies

Cited by 132

Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts

Tate, S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., & Cronier, D. M. (2014) · Clinical Cancer Research

Advanced Breast Cancer TherapiesMathematical Biology Tumor Growth

Cited by 130

Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity

Campbell, R. M., Anderson, B. D., Brooks, N. A., Brooks, H. B., Chan, E. M., De Dios, A., Gilmour, R., Graff, J. R., Jambrina, E., Mader, M., et al. (2014) · Molecular Cancer Therapeutics

Melanoma and MAPK PathwaysProtein Kinase Regulation and GTPase Signaling

Cited by 121

A first-in-human phase I study of the CDK4/6 inhibitor, LY2835219, for patients with advanced cancer.

Shapiro, G., Rosen, L. S., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Kulanthaivel, P., et al. (2013) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesCancer-related Molecular Pathways

Cited by 67

Elranatamab (PF-06863135), a B-Cell Maturation Antigen (BCMA) Targeted CD3-Engaging Bispecific Molecule, for Patients with Relapsed or Refractory Multiple Myeloma: Results from Magnetismm-1

Sebag, M., Raje, N. S., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Dube, H., Damore, M. A., et al. (2021) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 54

Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular Responses for Patients with Relapsed or Refractory Multiple Myeloma

Raje, N., Bahlis, N. J., Costello, C., Dholaria, B., Solh, M., Levy, M. Y., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., et al. (2022) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 46

Abstract CT232: clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 44

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

Bahlis, N. J., Raje, N. S., Costello, C., Dholaria, B. R., Solh, M. M., Levy, M. Y., Tomasson, M. H., Dube, H., Liu, F., Liao, K. H., et al. (2021) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 44

LY2835219, a novel cell cycle inhibitor selective for CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) metastatic breast cancer

Patnaik, A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 42

Clinical activity of LY2835219, a novel cell cycle inhibitor selective for CDK4 and CDK6, in patients with non-small cell lung cancer

Goldman, J. W., Gandhi, L., Patnaik, A., Rosen, L. S., Hilton, J. F., Papadopoulos, K. P., Tolaney, S. M., Beeram, M., Rasco, D. W., Myrand, S. P., et al. (2014) · Journal of Clinical Oncology

Lung Cancer Treatments and MutationsAdvanced Breast Cancer Therapies

Cited by 27

Clinical Activity of Abemaciclib (LY2835219), a Cell Cycle Inhibitor Selective for CDK4 and CDK6, in Patients with Relapsed or Refractory Mantle Cell Lymphoma

Morschhauser, F., Bouabdallah, K., Stilgenbauer, S., Thieblemont, C., Wolf, M., de Guibert, S., Zettl, F., Hahka-Kemppinen, M., Xiaohui Wang, D., Brueck, P., et al. (2014) · Blood

Lymphoma Diagnosis and TreatmentAdvanced Breast Cancer Therapies

Cited by 20

Elranatamab, a BCMA-targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma: Updated results from MagnetisMM-1.

Jakubowiak, A. J., Bahlis, N. J., Raje, N. S., Costello, C., Dholaria, B. R., Solh, M. M., Levy, M. Y., Tomasson, M. H., Dube, H., Damore, M. A., et al. (2022) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsCAR-T cell therapy research

Cited by 16

Abstract P5-19-13: clinical activity of abemaciclib, an oral cell cycle inhibitor, in metastatic breast cancer

Tolaney, S. M., Rosen, L. S., Beeram, M., Goldman, J. W., Gandhi, L., Tolcher, A. W., Papadopoulos, K. P., Rasco, D. W., Myrand, S. P., Kulanthaivel, P., et al. (2015) · Cancer Research

Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies

Cited by 13